June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
AAV5 made by rHSV complementation displays increased retinal transduction relative to AAV5 made by plasmid transfection.
Author Affiliations & Notes
  • Kevin Tyler Mccullough
    Ophthalmology, University of Florida, Gainesville, Florida, United States
  • Laura Adamson-Small
    Pediatrics, University of Florida, Gainesville, Florida, United States
  • James Peterson
    Ophthalmology, University of Florida, Gainesville, Florida, United States
  • Sanford Boye
    Ophthalmology, University of Florida, Gainesville, Florida, United States
  • Nathalie Clément
    Pediatrics, University of Florida, Gainesville, Florida, United States
  • Shannon Elizabeth Boye
    Ophthalmology, University of Florida, Gainesville, Florida, United States
  • Footnotes
    Commercial Relationships   Kevin Mccullough, None; Laura Adamson-Small, None; James Peterson, None; Sanford Boye, None; Nathalie Clément, UF Foundation (P); Shannon Boye, None
  • Footnotes
    Support  R01 EY024280 Research to Prevent Blindness
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4084. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Kevin Tyler Mccullough, Laura Adamson-Small, James Peterson, Sanford Boye, Nathalie Clément, Shannon Elizabeth Boye; AAV5 made by rHSV complementation displays increased retinal transduction relative to AAV5 made by plasmid transfection.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4084.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : AAV has emerged as the most promising vector for gene- based therapies to treat inherited retinal disease. To reduce immunogenicity, the ideal AAV vector prep should contain highly infectious particles and the lowest possible empty capsid load. With this in mind, different manufacturing platforms are being developed for generating large scale quantities of potent, clinical grade AAV, one of which relies on the recombinant Herpes simplex virus (rHSV) system. Notably, evidence in animal models and human clinical trials showed that AAV1 made by the rHSV system is more infectious that AAV1 made by plasmid transfection. Given that AAV5 is being developed for clinical use in the eye, we sought to determine relative levels of retinal transduction by AAV5 made by either the rHSV system or plasmid transfection.

Methods : Constructs containing the CMV promoter driving GFP and AAV2 rep-AAV5 cap were used separately to create respective rHSVs. HEK293 cells were infected with rHSVs or transfected with AAV plasmids containing the same CMV-GFP transgene, Adenoviral helper genes, AAV2 rep and AAV5 cap. Both AAV preps were purified by iodixanol density gradient and ion exchange chromatography. Vector genome titers were assessed by Q-PCR and infectivity was determined in vitro by green cell assay. Capsid were visualized by electron microscopy (EM) and Coomassie-stained SDS-PAGE. C57Bl6 mice were subretinally injected with two different doses (5x108 vg and 5x109 vg) of each vector. A larger cohort was then injected with 5x109 vg. At 4 and 8 weeks post injection (wpi), GFP expression was assessed by fundoscopy. Mice were sacrificed at 8 wpi and retinas collected for immunoblot and qPCR of GFP protein and RNA, respectively.

Results : AAV capsids made by rHSV and transfection appeared identical under EM and had roughly the same percentage of full and empty capsids. rHSV-AAV was substantially more infectious in vitro relative to transfection-made AAV. Transduction of mouse retina was also significantly higher in rHSV-AAV treated eyes when measured in vivo and in post-mortem retina.

Conclusions : AAV5 made by the rHSV complementation system displays enhanced transduction efficiency relative to transfection-made AAV5. Future clinical development of AAV5 based retinal gene therapies may benefit from the increased potency of rHSV made AAV5.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×